BS_KZPR01BD
DNET
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- DNET
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- DNET
- overall_survival_months
- 20.9592641261498
- age_years
- 6.655
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.563
- KRAS_SIGNALING_DN+0.306
- BILE_ACID_METABOLISM+0.302
- OXIDATIVE_PHOSPHORYLATION+0.256
- MYOGENESIS+0.225
- ESTROGEN_RESPONSE_LATE+0.213
- SPERMATOGENESIS+0.177
- ESTROGEN_RESPONSE_EARLY+0.127
- FATTY_ACID_METABOLISM+0.121
- PEROXISOME+0.113
Top 10 suppressed
- E2F_TARGETS-0.550
- G2M_CHECKPOINT-0.504
- MYC_TARGETS_V2-0.486
- IL6_JAK_STAT3_SIGNALING-0.471
- INTERFERON_GAMMA_RESPONSE-0.433
- TNFA_SIGNALING_VIA_NFKB-0.417
- INTERFERON_ALPHA_RESPONSE-0.406
- MYC_TARGETS_V1-0.402
- MITOTIC_SPINDLE-0.389
- DNA_REPAIR-0.383
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR818418 | GTEX | — | 0.921 |
| 2 | SRR1498640 | GTEX | — | 0.911 |
| 3 | SRR1474333 | GTEX | — | 0.889 |
| 4 | SRR1416999 | GTEX | — | 0.889 |
| 5 | BS_VMMJYN8Z | Ganglioglioma | — | 0.886 |
| 6 | SRR1316297 | GTEX | — | 0.883 |
| 7 | SRR1375571 | GTEX | — | 0.883 |
| 8 | BS_3PYESPHA | Ganglioglioma | — | 0.879 |
| 9 | SRR1381889 | GTEX | — | 0.878 |
| 10 | SRR1320115 | GTEX | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.563 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.306 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.302 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.256 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.225 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.213 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.177 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.127 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.121 | Inavolisib | — uncovered |
| PEROXISOME | 0.113 | Idelalisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.106 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.089 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.087 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.082 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.066 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.054 | Remibrutinib | — uncovered |
| UV_RESPONSE_UP | 0.022 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.007 | Temsirolimus | — uncovered |
| MTORC1_SIGNALING | 0.005 | Inavolisib | — uncovered |